ReviewFrontiers in oncology2025
Exosomes in lung cancer: a role in early diagnosis.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Panel of Circulating Exosomal sncRNAs Associated With Lung Cancer Risk up to 10 Years in Advance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.Cancer science · 2026Article
- The updated role of exosomes in cancer diagnosis and therapy.Discover oncology · 2026Review
- Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most prevalent and deadly malignant tumor in the world. Traditional treatment methods rely on histopathological analysis of cancer cells obtained through tissue biopsies, which carry risks due to their invasive nature. Thus, there is an urgent need to identify effective and non-invasive early screening methods for lung cancer. Exosomes, a crucial element of liquid biopsies, have emerged as a promising alternative due to their non-invasive collection, convenience and cost-effectiveness in diagnosing lung cancer. Research has underscored the role of exosomes in lung cancer invasion, metastasis, immune regulation, and the tumor microenvironment. Furthermore, the contents of exosomes, such as miRNAs, lncRNAs, circRNAs, and proteins, demonstrate considerable potential for the early diagnosis of lung cancer. This article provides a comprehensive review of the role and application of exosomes as liquid biopsy markers for early diagnosis of lung cancer, emphasizing their promise in improving patient outcomes through earlier detection and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.